Overcoming Challenges in the Current Biotech Landscape 24/06/2024 Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed... Partners
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for... 24/05/2024 Healthcare Access to innovation Innovative drugs Advanced therapies it is a medicine to improve progression-free survival and overall survival in patients with metastatic pancreatic... Partners
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
#NewAseBioMember | “This partnership gives us the possibility to establish key contacts an... 20/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal. AseBio - Kirsch Pharma España
Mikrobiomik launches strategic investment round to advance its first medicine based on the... 30/04/2024 Healthcare Drug discovery Rare diseases Innovative drugs The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first... Partners - Mikrobiomik
Creation of new 3D liver cell models for research 30/04/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies The main objective of the project is the creation of innovative in vitro models using microencapsulation of human liver... Partners - BeCytes Biotechnologies
